OncLive SOSS

Current and Future Trends in Myeloproliferative Neoplasms - Episode 14

Management of Accelerated Phase Myeloproliferative Neoplasms

August 11, 2022

Rami Komrokji, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center

Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Myeloproliferative Neoplasms: Essential Thrombocythemia

EP. 2: Managing Patients with Essential Thrombocythemia

EP. 3: Myeloproliferative Neoplasms: Polycythemia Vera

EP. 4: Treatment Options for Polycythemia Vera

EP. 5: PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera

EP. 6: Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms

EP. 7: Myeloproliferative Neoplasms: Myelofibrosis

EP. 8: Risk Stratification for Myelofibrosis

EP. 9: Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials

EP. 10: New JAK Inhibitors in Myelofibrosis Treatment

EP. 11: Efficacy and Safety of JAK Inhibitors for Myelofibrosis

EP. 12: Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022

EP. 13: Novel Agents Under Investigation for Myelofibrosis

EP. 14: Management of Accelerated Phase Myeloproliferative Neoplasms

EP. 15: Clinical Scenario: A 67-Year-Old with Myelofibrosis

EP. 16: Myelofibrosis Treatment Approaches after Disease Progression

EP. 17: Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis

EP. 18: The Future of Myeloproliferative Neoplasm Treatment

x